VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
RSP-1502
Preclinical
Small molecule
R
Respirion Pharmaceuticals Pty Ltd
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cystic Fibrosis Lung
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cystic Fibrosis Lung
Preclinical
Completed
Clinical
Trials by Indication
[1]
Cystic Fibrosis Lung
1 trial
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b/2a Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection
Completed
·
R
Respirion Pharmaceuticals Pty Ltd
·
Preclinical
·
NCT06016088
·
71 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for RSP-1502. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
RSP-1502 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for RSP-1502. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Respirion Pharmaceuticals Pty Ltd company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Preclinical
[1]
Company
R
Respirion Pharmaceuticals Pty Ltd
Related News